Zim Laboratories Quarterly Results for Trading Insights
In Mar 2026, Zim Laboratories (ZIMLAB) reported revenue ₹111 Cr and net profit ₹4 Cr — revenue +0.9% YoY. For annual financials, live price and key ratios, visit ZIMLAB share price screener.
ZIMLAB Quarterly Results — Revenue, Profit & EPS Highlights
Zim Laboratories latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore ZIMLAB stock price history to track price trends across different timeframes.
- Revenue of ₹111 Cr in Mar 2026 (+16.8% vs Jun 2026, +0.9% vs Mar 2025)
- Net Profit of ₹4 Cr in Mar 2026 (+200.0% vs Jun 2026, -20.0% vs Mar 2025)
- EBITDA of ₹13 Cr in Mar 2026 (+333.3% vs Jun 2026)
- Operating Margin of 7.0% in Mar 2026 (+4.0pp vs Jun 2026)
- Earnings Per Share of ₹0.76 in Mar 2026 (+201.3% vs Jun 2026)
Zim Laboratories Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ZIMLAB quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 111 | 95 | 91 | 110 | 73 | 16.8% | 0.9% |
| Net Profit (₹ Cr) | 4 | -4 | 0 | 5 | -2 | - | - |
| EBITDA (₹ Cr) | 13 | 3 | 8 | 16 | 6 | - | - |
| EPS (₹) | 0.76 | -0.75 | -0.09 | 1.01 | -0.38 | - | - |
| Operating Margin (%) | 7.0% | 3.0% | 6.0% | 13.0% | 6.0% | - | - |
ZIMLAB Share Price Trend — 1-Year Movement Across Quarterly Results
Zim Laboratories 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse ZIMLAB cash flow statement for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ZIMLAB vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Zim Laboratories latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹463,071.60 Cr | 1875.1 | 15,018 | 2,710 | -5.6% | - | 18.0% | 165.9 |
|
Divis Laboratories
Mar 2026 |
₹225,157.18 Cr | 8588.0 | 2,986 | 751 | -5.0% | - | 25.2% | 303.4 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4971.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.9 |
|
Cipla
Mar 2026 |
₹117,137.57 Cr | 1431.1 | 6,612 | 543 | -9.3% | - | 8.2% | 208.3 |
|
Zydus Life Science
Mar 2026 |
₹113,855.38 Cr | 1115.6 | 7,569 | 1,341 | -4.3% | - | 17.7% | 88.2 |
All amounts in ₹ Crores